In the latest trading session, 7.27 million Relmada Therapeutics Inc (NASDAQ:RLMD) shares changed hands as the company’s beta touched 0.34. With the company’s most recent per share price at $0.63 changed hands at -$2.14 or -77.21% at last look, the market valuation stands at $19.05M. RLMD’s current price is a discount, trading about -1046.03% off its 52-week high of $7.22. The share price had its 52-week low at $1.88, which suggests the last value was -198.41% down since then. When we look at Relmada Therapeutics Inc’s average trading volume, we note the 10-day average is 0.17 million shares, with the 3-month average coming to 191.54K.
Analysts gave the Relmada Therapeutics Inc (RLMD) stock a consensus recommendation rating of Sell, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 1 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RLMD as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Relmada Therapeutics Inc’s EPS for the current quarter is expected to be 0.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Instantly RLMD was in red as seen in intraday trades today. With action -76.79%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -84.75%, with the 5-day performance at -76.79% in the red. However, in the 30-day time frame, Relmada Therapeutics Inc (NASDAQ:RLMD) is -81.54% down. Looking at the short shares, we see there were 1.26 million shares sold at short interest cover period of 4.52 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need an upside of 68.5% from its recent market value. According to analyst projections, RLMD’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a -217.46% plunge from its current level, while the stock would need to soar -217.46% for it to hit the projected low.
Relmada Therapeutics Inc (RLMD) estimates and forecasts
Data shows that the Relmada Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -78.67% over the past 6 months, a 21.65% in annual growth rate that is considerably higher than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.94%. The 2024 estimates are for Relmada Therapeutics Inc earnings to increase by 17.38%.
RLMD Dividends
Relmada Therapeutics Inc is expected to release its next quarterly earnings report in January.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.04% of Relmada Therapeutics Inc shares while 46.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 50.09%. There are 46.06% institutions holding the Relmada Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 4.1706% of the shares, roughly 1.26 million RLMD shares worth $3.77 million.
DEEP TRACK CAPITAL, LP holds the second largest percentage of outstanding shares, with 4.0979% or 1.23 million shares worth $3.7 million as of 2024-06-30.
